GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (AMEX:AIM) » Definitions » PEG Ratio

AIM (AIM ImmunoTech) PEG Ratio : 0.00 (As of Dec. 13, 2024)


View and export this data going back to 1995. Start your Free Trial

What is AIM ImmunoTech PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, AIM ImmunoTech's PE Ratio without NRI is 0.00. AIM ImmunoTech's 5-Year EBITDA growth rate is 40.10%. Therefore, AIM ImmunoTech's PEG Ratio for today is 0.00.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for AIM ImmunoTech's PEG Ratio or its related term are showing as below:



AIM's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.69
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


AIM ImmunoTech PEG Ratio Historical Data

The historical data trend for AIM ImmunoTech's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech PEG Ratio Chart

AIM ImmunoTech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

AIM ImmunoTech Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of AIM ImmunoTech's PEG Ratio

For the Biotechnology subindustry, AIM ImmunoTech's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AIM ImmunoTech's PEG Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's PEG Ratio distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's PEG Ratio falls into.



AIM ImmunoTech PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

AIM ImmunoTech's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/40.10
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


AIM ImmunoTech  (AMEX:AIM) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


AIM ImmunoTech PEG Ratio Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AIM ImmunoTech Business Description

Traded in Other Exchanges
Address
2117 SW Highway 484, Ocala, FL, USA, 34473
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
Executives
Stewart Appelrouth director 2117 SW HIGHWAY 484, OCALA FL 34473
Thomas K. Equels director, officer: Vice Chairman of Board 2117 SOUTHWEST HIGHWAY 484, OCALA FL 34473
Rodino Peter W. Iii director 2117 SOUTHWEST HIGHWAY 484, OCALA FL 34473
Nancy Bryan director 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Ellen M Lintal officer: CFO 2117 SW HWY 484, OCALA FL 34473
William M Mitchell director 2117 SW HWY 484, OCALA FL 34473
Wayne S. Springate officer: VP of Operations 600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
David R Strayer other: Medical Director 600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
Adam Pascale officer: CFO 600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
Ralph Christopher Cavalli officer: VP, Quality Control 510 MURDOCH ROAD, PHILADELPHIA PA 19119
Russel J Lander officer: VP of Process/QualityAssurance 784 BAEDER ROAD, JENKINTOWN PA 19046
Robert Iv Dickey officer: Senior Vice President 320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Bernhardt Charles Thomas Iii officer: CFO 23 BIRCH ROAD, MALVERN PA 19355
Steven D Spence director 250 EAST 54TH STREET APARTMENT 36C, NEW YORK NY 10022
Anthony Bonelli officer: President & COO P.O. BOX 521, NEW VERNON NJ 07976